Turn Therapeutics (NASDAQ:TTRX) Issues Earnings Results

Turn Therapeutics (NASDAQ:TTRX) released its quarterly earnings results on Tuesday. The company reported ($0.09) earnings per share (EPS) for the quarter, Zacks reports.

Turn Therapeutics Stock Performance

NASDAQ TTRX traded down $0.08 on Wednesday, reaching $3.12. 11,001 shares of the stock traded hands, compared to its average volume of 30,389. Turn Therapeutics has a 12 month low of $2.57 and a 12 month high of $26.50. The company has a market capitalization of $91.87 million and a P/E ratio of -44.57. The stock’s fifty day moving average price is $3.71.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on TTRX shares. Weiss Ratings initiated coverage on shares of Turn Therapeutics in a report on Monday, January 5th. They issued a “sell (e-)” rating for the company. D. Boral Capital restated a “buy” rating and set a $8.00 price target on shares of Turn Therapeutics in a research report on Tuesday, March 24th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Turn Therapeutics presently has an average rating of “Hold” and an average target price of $8.00.

Institutional Trading of Turn Therapeutics

Institutional investors have recently modified their holdings of the company. HighTower Advisors LLC acquired a new stake in shares of Turn Therapeutics in the fourth quarter valued at $78,000. Geode Capital Management LLC acquired a new position in Turn Therapeutics during the fourth quarter worth about $68,000. LPL Financial LLC bought a new stake in Turn Therapeutics in the fourth quarter worth about $51,000. Hodges Capital Management Inc. acquired a new stake in Turn Therapeutics in the 4th quarter valued at about $39,000. Finally, Brown Brothers Harriman & Co. acquired a new stake in Turn Therapeutics in the 4th quarter valued at about $93,000.

Turn Therapeutics Company Profile

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.